HGF and arteriosclerosis obliterans: Thus, therapeutic applications of HGF have been tested in various diseases including liver cirrhosis, chronic renal failure, lung fibrosis, myocardial infarction, arteriosclerosis obliterans, amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), and acute spinal cord injury (Matsuda, 1997; Matsumoto, 2002; Matsumoto & Nakamura, 1998; Morishita et al., 2004; Powell et al., 2010; Sala & Crepaldi, 2011; Sanada et al., 2020; Takano et al., 2017; Ueki et al., 1999).